Alnylam Pharmaceuticals informa las ganancias trimestralmente. Estos informes de ganancias trimestrales ofrecen a los inversores una visión de los resultados financieros de una empresa durante un período de 3 meses. Los informes de ganancias casi siempre incluyen resultados de EPS e ingresos.
Analice el historial de beneficios de Alnylam Pharmaceuticals utilizando filtros y clasificaciones avanzadas.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY | Alnylam Pharmaceuticals | -$0.50 | $1.23 | $2.90 | 135.77% | $500.92M | $992.47M | $1.25B | 25.85% | 10/30/2025 | |
ALNY | Alnylam Pharmaceuticals | $0.58 | -$0.16 | $0.32 | 300.00% | $659.83M | $660.99M | $773.69M | 17.05% | 07/31/2025 | |
ALNY | Alnylam Pharmaceuticals | -$0.16 | -$1.03 | -$0.01 | 99.03% | $494.33M | $585.82M | $594.19M | 1.43% | 05/01/2025 | |
ALNY | Alnylam Pharmaceuticals | -$0.77 | -$0.14 | $0.06 | 142.86% | $439.72M | $580.62M | $593.17M | 2.16% | 02/13/2025 | |
ALNY | Alnylam Pharmaceuticals | $1.74 | -$0.93 | -$0.50 | 46.24% | $750.53M | $533.10M | $500.92M | -6.04% | 10/31/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.62 | -$1.08 | $0.56 | 151.85% | $318.75M | $444.11M | $659.83M | 48.57% | 08/01/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.06 | -$1.18 | -$0.16 | 86.44% | $319.29M | $427.33M | $494.33M | 15.68% | 05/02/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.39 | -$1.33 | -$0.77 | 42.11% | $335.04M | $442.90M | $439.72M | -0.72% | 02/15/2024 | |
ALNY | Alnylam Pharmaceuticals | -$1.58 | -$1.36 | $1.74 | 227.94% | $264.31M | $401.03M | $750.53M | 87.15% | 11/02/2023 | |
ALNY | Alnylam Pharmaceuticals | -$2.03 | -$1.72 | -$1.62 | 5.81% | $224.82M | $331.73M | $318.75M | -3.91% | 08/03/2023 | |
ALNY | Alnylam Pharmaceuticals | -$1.49 | -$1.76 | -$1.06 | 39.77% | $213.26M | $312.26M | $319.29M | 2.25% | 05/04/2023 | |
ALNY | Alnylam Pharmaceuticals | -$1.74 | -$1.90 | -$1.39 | 26.84% | $258.54M | $313.13M | $335.04M | 7.00% | 02/23/2023 | |
ALNY | Alnylam Pharmaceuticals | -$1.59 | -$1.78 | -$1.58 | 11.24% | $187.63M | $293.03M | $264.31M | -9.80% | 10/27/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.30 | -$1.62 | -$2.03 | -25.31% | $220.55M | $255.88M | $224.82M | -12.14% | 07/28/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.64 | -$1.84 | -$1.49 | 19.02% | $135.77M | $243.02M | $213.26M | -12.25% | 04/28/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.60 | -$1.54 | -$1.69 | -9.74% | $163.56M | $233.62M | $258.54M | 10.66% | 02/10/2022 | |
ALNY | Alnylam Pharmaceuticals | -$1.58 | -$1.57 | -$1.51 | 3.82% | $125.85M | $218.69M | $187.63M | -14.20% | 10/28/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.67 | -$1.60 | -$1.30 | 18.75% | $103.96M | $193.18M | $220.55M | 14.17% | 08/03/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.52 | -$1.75 | -$1.64 | 6.29% | $99.48M | $168.74M | $177.57M | 5.23% | 04/29/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.98 | -$1.76 | -$1.60 | 9.09% | $71.68M | $146.07M | $163.56M | 11.98% | 02/11/2021 | |
ALNY | Alnylam Pharmaceuticals | -$1.50 | -$1.66 | -$1.58 | 4.82% | $70.06M | $120.75M | $125.85M | 4.23% | 11/05/2020 |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | 2025-10-30 | $2.90 | $1.23 | 135.8 % |
| Q2 | 2025-07-31 | $0.32 | $-0.16 | 300.0 % |
| Q1 | 2025-05-01 | $-0.01 | $-1.03 | 99.0 % |
| Q4 | 2025-02-13 | $0.06 | $-0.14 | 142.9 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | 2025-10-30 | $1.25B | $992.47M | 25.9 % |
| Q2 | 2025-07-31 | $773.69M | $660.99M | 17.1 % |
| Q1 | 2025-05-01 | $594.19M | $585.82M | 1.43 % |
| Q4 | 2025-02-13 | $593.17M | $580.62M | 2.16 % |
Alnylam Pharmaceuticals (ALNY) aún no tiene ningún informe de resultados previsto. El último informe de resultados se publicó el octubre 30, 2025 para el Q3.
Alnylam Pharmaceuticals (ALNY) aún no tiene ningún informe de resultados previsto. El último informe de resultados se publicó el octubre 30, 2025 para el Q3 y el BPA real fue de $2.90, que superó la estimación de $1.23.
Alnylam Pharmaceuticals (ALNY) aún no tiene ningún informe de resultados previsto. El último informe de resultados se publicó el octubre 30, 2025 para el Q3 y los ingresos reales fueron de $1.2B, que superó la estimación de $992.5M.
Explora Estimaciones de beneficios, BPA e ingresos sobre todos los valores.